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ABSTRACT
Background: Elevated levels of circulating branched-chain amino acids (BCAA)
and ketone bodies are recognized as biomarkers for cardiovascular disease
(CVD) and other pathological conditions in type-2 diabetes mellitus (T2DM).
Aerobic exercise interventions have been shown to decrease the levels of these
markers, suggesting improved metabolic status and reduced risk of CVD.
However, the efficacy of resistance training and concurrent programs in reducing
BCAA and ketone body levels has not been well researched.
Methods: The current study was performed as a secondary analysis of the
HART-D trial, a 9-month randomized, controlled exercise-training trial of 262
participants with T2DM. Participants were randomized to one of four groups: nonexercise control, aerobic training (AT), resistance training (RT), or a combined
aerobic and resistance training (ATRT). The effects of the 9-month intervention
on BCAAs (leucine, valine, and isoleucine) and ketone bodies (β-hydroxybutyrate, BHB; acetoacetate, AcAc; and acetone) were quantified by nuclear
magnetic resonance spectroscopy (NMR) at LabCorp (Morrisville, NC).
Generalized linear models were used to examine effects of exercise training
between groups with adjustments for age, sex, race, change in fat mass,
glucose, and medication status and baseline trait value. Pearson correlation
analysis was used to examine associations of the changes in BCAA and ketone
levels with changes in concomitant cardiometabolic biomarkers.
ii

Results: The ATRT group increased total BCAA and leucine levels compared to
the AT group, and increased isoleucine compared to all other groups (all p<0.05).
RT decreased BHB levels (p<0.05) compared to the AT group only. Across all
exercise groups combined, changes in total ketone bodies (r=0.2), BHB (r=0.21),
and Acetone (r=0.17) were weakly correlated with changes in HbA1c levels.
Changes in total BCAAs (r=0.30) and valine (r=0.36) were moderately correlated
with changes in fasting glucose levels, while isoleucine was weakly correlated
with glucose (r=0.2) (all p<0.05).
Conclusions: Our results show that the ATRT group increased isoleucine levels
compared to the control group in diabetics, the mechanism of which is unclear.
Exercise induced changes in BCAA and ketone body levels are weakly to
moderately related to some concomitant cardiometabolic biomarkers such as
fasting glucose and HbA1c levels. Further research is needed to examine the
association of exercise training on circulating BCAA and ketone body levels in
diabetics.
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CHAPTER 1
INTRODUCTION
The branched-chain amino acids (BCAA); leucine, valine, and isoleucine
are essential amino acids that distinguish themselves from the other amino acids
due to very limited hepatic catabolism1. The majority of their metabolism resides
in skeletal muscle. As such they play an important role in regulating muscle
protein synthesis, and contributing to energy production via the tricarboxylic acid
(TCA) cycle2. BCAAs are metabolized through two main processes. The first, a
reversible transamination catalyzed by branched-chain aminotransferase
(BCAT), produces branched chain α-ketoacids (BCKA) and glutamate. The
second, is an irreversible oxidative decarboxylation of the BCKAs catalyzed by
the branched chain α-ketoacid dehydrogenase (BCKDH) complex3. The complex
is regulated by both covalent and allosteric mechanisms. Phosphorylation of its
E1 component by BCKDH kinase downregulates activity, while mitochondrial
protein phosphatase 2C (PP2Cm) dephosphorylates the complex, upregulating
its activity1. BCKAs, specifically α-ketoisocaproate, can bind the BCKDH kinase
and allosterically inhibit the phosphorylation of the complex, suggesting that
deficiencies in BCAT activity could downregulate BCKDH activity4. A deficiency in
the BCKDH complex can reduce its contribution to energy production and lead to
a buildup of circulating BCAAs in the blood.
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While the relationship is not completely understood, there appears to be
an association between elevated levels of circulating BCAAs and T2DM, and
related pathologies, such as cardiovascular disease (CVD)5-7. Improvements in
insulin resistance levels, as measured by the homeostatic model assessment of
insulin resistance (HOMA-IR), after weight loss have been found to have a
greater correlation with decreases in BCAA levels (r=0.50) than the amount of
weight lost (r=0.24) during an exercise intervention5. Elevated BCAA levels have
also been identified as strong predictors of the development of T2DM as they
have been shown to increase long before the onset of the condition 6. Increased
baseline levels of BCAAs more than doubled the risk of developing T2DM over a
six-year period in men (OR 2.09: 95%CI 1.38-3.17)6. Tobias et al8 discovered a
positive relationship between BCAA levels and coronary cardiovascular events in
women both with and without T2DM, although the relationship was stronger in
the diabetic population (Relative Risk 1.2: CI 1.08-1.32). This association has
also been reproduced in other prospective cohort trials7,9. While there hasn’t
been a determined causal link between BCAAs and CVD, impairment of BCAA
catabolic pathways in the heart was associated with elevated superoxide
production, oxidative injury, and mitochondrial permeability transition pore
opening in heart failure10,11.
Since BCAAs can be metabolized in skeletal muscle, unlike other amino
acids, they can contribute to energy production during exercise. Therefore
exercise has a large regulatory effect on the metabolism of BCAAs12. Aerobic
exercise acutely13-15 and chronically16 increases BCKDH activity and decreases
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expression of the BCKDH kinase protein. Due to enhanced oxidative capacity17
and increased protein turnover18 in skeletal muscle from resistance training it is
thought that regular resistance training would be beneficial in regulating BCAA
metabolism, however no actual studies have been performed to date. One study
looking at a concurrent exercise training program has been conducted which
showed a decrease in isoleucine and valine levels, however leucine levels did
not significantly decrease19.
Ketone bodies are molecules produced by the liver as a result of fatty acid
oxidation under conditions of low glucose availability20. The β-oxidation of fatty
acids results in acetyl-CoA, which can be converted via multiple steps of
enzyme-catalyzed reactions into one of three ketone bodies: acetoacetate
(AcAc), 3-β-hydroxybutyrate (BHB), or the least abundant, acetone. They are
mainly thought of as an alternate energy source, but can also be important
mediators of cell signaling, drivers of protein post-translational modification, and
modulators of inflammation and oxidative stress21. The rate of production of
ketones is controlled by acetyl-CoA carboxylase and mitochondrial HMG-CoA
synthase22, and the rate of clearance is regulated by succinyl-CoA-3-oxoacid
CoA transferase (SCOT)23 and monocarboxylate transporters (MCT1)24
Due to the role of insulin in regulating ketone production and metabolism,
ketones are a metabolite with strong implications in T2DM20. Diabetic
ketoacidosis is a serious condition that arises in diabetics, when ketone
production becomes too deregulated25. In a study of over 9,000 men; levels of
ketone bodies (AcAc & BHB) were significantly increased (p<0.01) in those with
3

diabetes compared to those with normal glucose control26. AcAc levels were
increased by elevated in diabetics by 64% (95% CI, 16% to 109%), and BHB
levels were increased by 99% (95% CI, 6% to 186%) compared with the
reference group. After a five year follow up of over 4,000 of these men, elevated
AcAc levels were associated with increased risk of incident T2DM in those with
impaired fasting glucose (OR 1.49: 95%CI 1.12-1.99)26. Lower levels of
adipocyte RNA expression of key enzymes in ketolysis, such as SCOT, were
also found in those with diabetes and glucose tolerance issues26. Altered
substrate utilization in myocardial metabolism is known to play a causative role in
the development of CVD in those with diabetes27,28. A 2001 study29 found that
ketone body utilization in patients with heart failure is altered in a tissue specific
manner. Skeletal muscle has a significantly lower uptake of ketones in heart
failure patients than in healthy controls. Therefore, elevated levels of ketone
bodies are often observed in patients with heart failure29.
Due to the role of ketones as a fuel source under certain conditions,
exercise can affect plasma ketone levels acutely and alter them chronically
through both ketogenic inhibiting and ketolytic enhancing mechanisms. Since the
rate of ketogenesis is increased as the ratio of glucagon to insulin increases,
chronically, exercise works to inhibit the excess rates of ketogenesis by
increasing insulin sensitivity in type 2 diabetics30,31. While specific long term
training induced changes in expression of ketolytic enzymes has not yet been
described in humans, changes are observed in ketone body metabolism during
and after exercise in trained and untrained individuals, such as the attenuation of
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post-exercise rises in ketone bodies32. However, rodent models have shown
increased expression of ketolytic enzymes such as SCOT33 and MCT124 from
aerobic training programs in an intensity dependent manner.
In summary, circulating BCAAs and ketone bodies are heavily implicated
with the development of T2DM and mediate some of the comorbidities and
disease states that are synonymous with the condition, especially CVD. While
some research has been published with promising results regarding the efficacy
of regular exercise to manage these biomarkers, there is limited information on
different training modalities or the pathways mediating these effects. In the
original analyses performed on the HART-D cohort, their main outcome trait
(HbA1c levels) was decreased compared to the control only in the combination
training group (-0.34%: 95% CI, -0.64% to -0.3%)34. Therefore, it is of interest to
research the effect of different training modalities on the levels of circulating
BCAAs and ketone bodies to further develop our understanding and
management of these biomarkers of complications in T2DM. We hypothesize
that all modalities of exercise will elicit significant changes in circulating BCAAs
and ketone bodies. We will test these hypotheses with the following aims:
Aim 1: Determine the association of different modalities of 9-month exercise
training plan on circulating BCAA and ketone levels in type 2 diabetics from the
HART-D study.
a. Determine the association of an aerobic training program on circulating BCAA
and ketone levels
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b. Determine the association of a resistance training program on circulating
BCAA and ketone levels
c. Determine the association of a combined aerobic and resistance training
program on circulating BCAA and ketone levels
We hypothesize that all exercise training modalities will significantly decrease
circulating BCAA and ketone levels and ATRT will produce significantly greater
decreases than AT and RT.
Aim 2: Determine the association of exercise induced changes in circulating
BCAA and ketones with changes in concomitant cardiometabolic biomarkers
(body fat %, lean mass, HbA1c, fasting glucose, fasting insulin, C-reactive
protein, and Vo2peak) in type 2 diabetics from the HART-D study.
We hypothesize that exercise induced changes in circulating BCAA and ketone
levels will be associated with changes in concomitant cardiometabolic
biomarkers with no significant differences between groups.
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CHAPTER 2
BCAAS AND KETONE BODIES IN DIABETES
Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by
apoptosis and dysfunction of pancreatic β cells due to a decrease in insulin
receptor sensitivity referred to as insulin resistance35. Chronic insulin resistance
causes an upregulation of glucose transporter 2 (GLUT2) channels which leads
to an increase in cytosolic calcium levels35, 36. These increased calcium levels
cause the subsequent β cell apoptosis due to calcium activated intracellular
cysteine protease calpain-237, and increased reactive oxygen species (ROS)38, 39.
Calcium stimulates ROS through both, increased mitochondrial ROS
metabolism38 and the NADPH oxidase dependent generation of ROS due to
activation of protein kinase C (PKC)39. The pancreatic β cells are believed to
have increased exposure to ROS due to aging40, chronic hyperglycemia41, and
elevated intracellular fatty acids42, which has led to the notion that advanced age,
poor diet, and sedentary lifestyle have a deleterious effect on β cell function and
play a role in the development of T2DM40-42.
Through large systematic reviews and meta-analyses, a plethora of risk
factors have been identified and evaluated for their efficacy in predicting T2DM
outcomes. Factors pertaining to diet and lifestyle habits, psychosocial factors,
medical history, and blood biomarkers have been strongly linked to T2DM43.
7

Obesity is the strongest risk factor known, with metabolically unhealthy obesity
being associated with a 10-fold increase for the development of T2DM43. Lifestyle
factors that promote obesity, such as increased sedentary time [risk ratio (RR)
1.9: 95% Confidence Interval (CI) 1.66-2.19], smoking (RR 1.4: CI 1.33-1.44),
and increased sugar-sweetened beverage (RR 1.3: CI 1.21-1.41) and processed
meat consumption (RR 1.4: CI 1.25-1.49) also therefore increase the risk of
developing T2DM43. Biomarkers including C-reactive protein (RR 1.26: CI 1.161.37), alanine aminotransferase (RR 1.85: CI 1.57-2.18), and gamma-glutamyl
transferase (RR 1.92: CI 1.66-2.21) are all positively associated with T2DM risk,
while increased Vitamin D levels (RR 0.62: CI 0.54-0.70) are a negative risk
factor43.
Along with the transparent metabolic pathology of T2DM, there are a
number of complications and comorbidities associated with the disease.
Common complications of T2DM include hypertension, dyslipidemia, decreased
glomerular filtration rate, and peripheral vascular disease44. In addition to the
physical comorbidities that present themselves, an increased risk for mild
cognitive impairment and depression is associated with T2DM45. Rates of
clinically relevant depression among those afflicted with T2DM has been shown
to be about 31%46 which is much higher than the rates in the general population.
Diabetes and its’ complications are having a drastically increasing societal
and economic impact on the United States. Over the 20 year period from 1990 to
2010, the total number of adults diagnosed with diabetes tripled, while the
incidence rate over that time period doubled47, with type 2 being the vastly more
8

prevalent diagnosis48. Based on data from the 2016 National Health Interview
Survey, there are 21 million adults in the United States currently diagnosed with
T2DM48, which equates to 8.58% of the population. Along with the myriad of
health complications and comorbidities associated with it, adults diagnosed with
diabetes have a 50% higher all-cause mortality rate than those without the
diagnosis49. On top of the individual burden brought upon those diagnosed with
diabetes, the burden on the healthcare system is enormous. In 2017, the cost of
diabetes to the US healthcare system was $237 billion, more than double the
$116 billion it cost in 200750. This total accounts for roughly a quarter of all
healthcare dollars spent, and equals out to an average cost of $16,572 per
annum for each individual with the condition50.
Cardiovascular disease (CVD) is the leading cause of death in the United
States, attributing to approximately one third of total deaths in 201651. The risk for
developing CVD increases in diabetics one to three times for women and two to
five times for men. Diabetics have 1.7 times the mortality risk from CVD52.
Additionally, on average, atherosclerotic cardiovascular disease manifests itself
14.6 years earlier in those with T2DM than the non-diabetic population53. There
are many cellular and molecular pathophysiologic factors that elucidate the
increased incidence and severity of cardiovascular disease in the diabetic
population. The impairment of insulin signaling, hyperinsulinemia, and
hyperglycemia presented by type-2 diabetics contributes to numerous issues
such as elevated free fatty acids, protein kinase-C activation, mitochondrial
dysfunction, oxidative stress, and advanced glycogen end-product, which causes
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endothelial dysfunction and inflammation52. This leads to an increase in the
formation of foam cells in the vulnerable subendothelial layers of vasculature.
These foam cells release inflammatory mediators such as tumor necrosis factorα, leading to stenosis and necrosis of the vessel52.
Exercise has long been identified as a key factor in the prevention and
management of T2DM. The most recent American Diabetes Association
guidelines recommend at least 150 minutes per week of moderate to vigorous
aerobic exercise and 2-3 days per week of resistance training54. The efficacy of
aerobic exercise in the management and prevention of diabetes has been well
studied with positive results. Lifestyle interventions in the form of dietary energy
restriction and 150-175 minutes per week of aerobic exercise have shown a 4070% reduction in the risk of developing T2DM in subjects with impaired glucose
tolerance54. Aerobic exercise has been shown to improve many markers
associated with dysfunction in diabetics such as glycosylated hemoglobin levels,
regulation of lipid and lipoprotein metabolism55, insulin resistance, fasting plasma
glucose, fasting insulin, and systolic blood pressure56. More recently it has been
acknowledged that resistance training is also a viable method of exercise to
combat diabetes related complications. Along with the obvious beneficial
physiological adaptations caused by resistance training, such as increased lean
body mass, strength, and bone mineral density, it also has been shown to reduce
HbA1c and blood pressure, and increase insulin sensitivity in type 2 diabetics30.
There is an inverse association between skeletal muscle index, the ratio of
estimated total skeletal muscle mass as a ratio of total body weight, and
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developing insulin resistance. From the lowest quartile to the second lowest
quartile the RR is 0.72 (CI 0.63-0.83) and from the lowest to highest quartile the
RR is 0.59 (CI 0.48-0.72)31. This suggests resistance training may be important
and beneficial in the diabetic population. There is evidence that a concurrent
(resistance and aerobic training) program produces greater results than either
modality by itself. Concurrent programs have been shown to produce greater
improvements in body composition and performance characteristics, such as
lean body mass, fat mass, strength, and VO2max, as well as HbA1c levels34, and
pro-inflammatory biomarkers such as interleukin-6 and tumor necrosis factor-α57.
A factor that has more recently been identified as having a strong
association with metabolic disease and CVD is the circulating level of branchedchain amino acids (BCAA) and their metabolites58. Metabolic profiling shows that
changes in circulating levels of BCAAs have an inverse association with insulin
sensitivity (r=-0.38), and are a potential predictor of CVD risk59. The BCAAs;
leucine, valine, and isoleucine are essential amino acids that play an important
role in activating the anabolic signaling molecule, mammalian target of
rapamyacin complex 1 (MTOR1C), regulating muscle protein synthesis, and
energy production2. BCAAs are broken down through two main processes, the
first catalyzed by branched-chain aminotransferase (BCAT), and the second
catalyzed by the branched chain α-ketoacid dehydrogenase complex (BCKDH)3.
In the first process, BCAT catalyzes the transamination of BCAAs, a substitution
reaction that replaces the amine functional group of the BCAA with a ketone
group to form branched-chain α-keto-acids(BCKA) and glutamate. In the BCKDH
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complex the BCKA products then undergo oxidative decarboxylation to produce
acyl-CoA derivatives which are subsequently converted through several
downstream reactions into acetyl-CoA and succinyl-CoA which enter the
tricarboxylic acid (TCA) cycle to be involved in energy production60. A deficiency
in the BCKDH complex can reduce its contribution to energy production and lead
to a buildup of BCAAs in the blood. Adipose specific over-expression of GLUT-4
creates a concerted decrease in multiple BCAA catabolic enzymes in adipose
tissue, resulting in increased levels of circulating BCAAs61. Deficiencies in the
BCKDH complex can often be caused by overexpression of BCKDH kinase, an
inhibitor of the complex, and a decrease in expression of mitochondrial BCAT,
which catalyzes the initial transamination of BCAAs to produce BCKA for
oxidative decarboxylation via the BCKDH complex62.
While the relationship is not completely understood, there appears to be
an association between T2DM and elevated levels of circulating BCAAs.
Improvements in insulin resistance levels, as measured by the homeostatic
model assessment of insulin resistance, after weight loss have been found to
have a greater correlation with decreases in BCAA levels (r=0.50) than the
amount of weight lost (r=0.24) during an exercise intervention 59. Elevated BCAA
levels have also been shown to be strong predictors of the development of T2DM
as they have been shown to increase long before the onset of the condition 5.
Increased baseline levels of BCAAs more than doubled the risk of developing
T2DM over a six year period in men (OR 2.09: CI 1.38-3.17)5. Increased levels of
BCAAs, BCKAs, and medium and long‐chain acylcarnitines, by‐products of
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mitochondrial catabolism of BCAAs, all distinguish between obese people who
have features of insulin resistance versus those who do not3.
There are several hypotheses as to how BCAA levels might affect insulin
resistance especially in those with T2DM. There are some genetic factors, as
genetic variants in the protein phosphatase, Mg2+/Mn2+ dependent 1K, are
associated with T2DM. The PPM1K gene is responsible for encoding the
mitochondrial protein phosphatase 2C (PP2Cm) which activates the BCKDH
complex through dephosphorylation6. There are also theories involving the
MTORC1 pathway. Activation of the MTORC1 pathway involves insulin and
glucose, as well as crucially requiring BCAAs for signaling of translocation to the
lysosome, so an overload of BCAA could play a role in developing insulin
resistance63 with MTOR being a central signal in cross-talk between BCAAs and
insulin64. There is also some evidence to suggest that inhibition of sodiumglucose cotransporter-2 increases BCAA metabolism and therefore the sodiumglucose cotransporter-2 may play a role in BCAA levels in T2DM as expression
of these proteins is increased in diabetic nephropathy65.
While the relationship between BCAA’s and T2DM is relatively well
documented, the association of BCAAs with CVD is more contentious. Tobias et
al8 discovered a positive relationship between BCAA levels and coronary
cardiovascular events in women both with and without T2DM, although the
relationship was stronger in the diabetic population (RR 1.2: CI 1.08-1.32). This
association has been reproduced in other prospective cohort trials7, 9, however
some studies have found that after adjusting for cofounding variables, BCAA
13

levels are not a significant predictor of cardiovascular events66. While there
hasn’t been a determined causal link between BCAAs and CVD, a recent study
found that impairment of BCAA catabolic pathways in the heart was associated
with elevated superoxide production and oxidative injury10, and were regulated by
Kruppel-like factor 15 in which deficiencies have been shown to be linked to
CVD67.
As BCAAs, unlike other amino acids, can be metabolized in skeletal
muscle, they can contribute to energy production during exercise, and therefore
exercise has a large regulatory effect on the metabolism of BCAAs12. Aerobic
exercise acutely increases BCAA metabolism by activating the BCKDH
complex13-15 and decreasing BCKDH Kinase activity15. Chronic repeated bouts of
aerobic exercise decrease BCKDH Kinase protein expression in skeletal muscle,
thereby increasing activation of the BCDKH complex16. Exercise intolerance may
develop in severe cases of deficiencies in BCAA metabolism, as exhibited in
studies with BCAT knockout mice68.
There is very little information to date on the impact of resistance training
on BCAA metabolism. Due to the increased oxidative capacity in skeletal muscle
from enhanced mitochondrial function17 and stimulation of muscle protein
turnover18, it would be assumed to have a beneficial effect. The effects of a
combined program of aerobic and resistance training on BCAA levels have been
studied only once. In this study, leucine levels did not change with training,
however, isoleucine and valine levels did decrease19. Due to the lack of studies
regarding resistance and combination training, there is a need for further
14

research to increase our understanding of the efficacy of different modes of
exercise as a treatment for lowering or maintaining circulating BCAA levels. It is
also not known how exercise induced changes in BCAAs correlate with changes
in some other important concomitant cardiometabolic biomarkers related to
T2DM, such as HbA1c, C-reactive protein, and lipid panel. There is no accepted
working model as to the exact physiological mechanisms underlying enhanced
BCAA metabolism from exercise, and therefore the biological plausibility needs
to be further examined.
Ketone bodies are molecules produced by the liver as a result of fatty acid
oxidation under conditions of low glucose availability20. They are mainly thought
of as an alternate energy source, but can also be important mediators of cell
signaling, drivers of protein post-translational modification, and modulators of
inflammation and oxidative stress21. Normal ketone levels are below 0.6mmol/L,
however issues with hormonal balance or enzyme malfunctions in ketolysis can
lead to a build-up of unused ketone bodies in the blood, which causes a drop in
pH and acidosis. The β-oxidation of fatty acids results in acetyl-CoA, which can
be converted via multiple steps of enzyme-catalyzed reactions into one of three
ketone bodies: acetoacetate (AcAc), 3-β-hydroxybutyrate (3HB), or the least
abundant, acetone.
The rate of production of ketones is controlled by three hormones:
hormone-sensitive lipase, acetyl-CoA carboxylase, and mitochondrial HMG-CoA
synthase. The activity of these hormones is determined by the ratio of circulating
levels of insulin and glucagon20. Ratios favoring insulin act to inhibit ketogenesis,
15

while when glucagon is favored ketone production is stimulated22. Glucagon
signals for the body to raise the concentration of glucose in the bloodstream
whereas insulin lowers the concentration, signaling for the uptake of glucose into
tissues to be used for energy production22. When the levels of glucagon are
higher than insulin it promotes fatty acid oxidation in order to produce acetyl-CoA
for energy production through the TCA cycle. If glucagon levels are raised too
much, due to issues such as insulin resistance, acetyl-CoA production via fatty
acid oxidation may increase beyond the body’s need for it as an energy substrate
and will instead be converted to ketone bodies to be stored instead of entering
the TCA cycle69. Insulin also promotes peripheral ketone body clearance, thus
reduced insulin levels will cause increased plasma ketone levels due to both
enhanced ketogenesis and diminished ketolysis70.
Succinyl-CoA-3-oxoacid CoA transferase (SCOT) is an enzyme derived
from the OXCT1 gene that catalyzes the transfer of CoA between carboxylic acid
groups23. SCOT catalyzes the first and rate determining step of ketolysis by
transferring a CoA group from succinyl-CoA to acetoacetate to form acetoacetylCoA, which is further broken down into two acetyl-CoA groups to enter the TCA
cycle for energy production71. Deficiencies in SCOT interfere with the ability to
utilize ketones as an energy source, as the process of ketolysis cannot be
initiated in order to produce Acetyl-CoA groups for the TCA cycle. As a result
they build up in the blood and can cause recurrent episodes of ketoacidosis 23.
Monocarboxylate transporters (MCT1) are responsible for the transport of
ketones through the cell membrane. Loss of function or decreased expression in
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MCT1 can therefore reduce uptake in organs to cause elevated circulating
ketone bodies24.
Due to the role of insulin in regulating ketone production and metabolism,
ketones are a metabolite with strong implications in T2DM20. Diabetic
ketoacidosis is a serious condition that arises in diabetics, when ketone
production becomes too deregulated. It is characterized by blood glucose levels
of more than 13.9mmol/L, serum ketone levels of more than 3.0 mmol/L and
arterial pH of less than 7.325. In a study of over 9,000 men; levels of ketone
bodies (AcAc & BHB) were significantly increased (p<0.01) in those with diabetes
compared to those with normal glucose control26. AcAc levels were increased by
elevated in diabetics by 64% (95% CI, 16% to 109%), and BHB levels were
increased by 99% (95% CI, 6% to 186%) compared with the reference group.
After a five year follow up of over 4,000 of these men, elevated AcAc levels were
associated with increased risk of incident T2DM in those with impaired fasting
glucose (OR 1.49: 95%CI 1.12-1.99)26. Lower levels of adipocyte RNA
expression of key enzymes in ketolysis, such as SCOT, were also found in those
with diabetes and glucose tolerance issues26.
Dysregulation of ketone levels in diabetics is a multi-factorial issue that
stems from several deficiencies and pathologies caused by the condition within
both the endocrine system and enzymatic proteins. The effects of T2DM on
insulin resistance and β-cell function cause disparity in the glucagon/insulin ratio,
which promotes ketogenesis and the diminished insulin secretion can also cause
decreases in ketolysis70. Increased activity of free radicals of nitrogen and
17

oxygen species in diabetics can lead to non-enzymatic nitration of tyrosine
residues of SCOT, which attenuate its function, as has been reported in diabetic
mice models72. MCT1 expression is also lowered due to decreases in lactate
production as a result of insulin resistance73 as well as muscle inactivity74 due to
sedentary lifestyle.
Altered substrate utilization in myocardial metabolism is known to play a
causative role in the development of CVD in those with diabetes27, 28. Ketone
metabolism is one substrate associated with cardiovascular events. One
characteristic of CVD, such as cardiomyopathy, is decreased utilization of fatty
acid oxidation for energy production in the cardiac muscle tissue, leading to an
increase in glucose utilization in the heart28. Increased glucose utilization results
in increased rates of gluconeogenesis and therefore acetyl-CoA produced by
fatty acid oxidation is broken down into ketone bodies rather than reacting with
oxaloacetate to enter the TCA cycle20. A 2011 study29 found that ketone body
utilization in patients with heart failure is altered in a tissue specific manner.
Skeletal muscle has a significantly lower uptake of ketones in heart failure
patients than in healthy controls. Therefore, elevated levels of ketone bodies are
often observed in patients with heart failure29. Further highlighting the importance
of ketones in CVD, patients with recessive mutations of the OXCT1 gene that
encodes the SCOT protein often present with dilated cardiomyopathy due to
defects in ketone body metabolism75.
Due to the role of ketones as a fuel source under certain conditions,
exercise can affect plasma ketone levels acutely and alter them chronically
18

through both ketogenic inhibiting and ketolytic enhancing mechanisms. Since the
rate of ketogenesis is increased as the ratio of glucagon to insulin increases,
chronically, exercise works to inhibit the excess rates of ketogenesis by
increasing insulin sensitivity in type 2 diabetics30, 31. Acute exercise promotes the
ketolytic pathways to increase ketone body clearance. The relationship between
plasma ketone concentrations and skeletal muscle oxidation of ketones is
curvilinear with saturation kinetics. The contribution of ketones to skeletal muscle
ATP production increases with elevating concentrations until it reaches saturation
levels at approximately 1-2mmol/L and then declines as the concentrations
increase further76, 77.
While specific long term training induced changes in expression of
ketolytic enzymes has not yet been described in humans, changes are observed
in ketone body metabolism during and after exercise in trained and untrained
individuals, such as the attenuation of post-exercise rises in ketone bodies32.
However, these enzymatic pathways have been studied more in rodent models
and suggest that intense aerobic exercise training results in increased
expression of ketolytic enzymes SCOT, BDH, and ACAT33. It has been well
established that MCT1 expression increases with training in an intensity
dependent manner, to increase cells uptake of ketones24, 78. While research is
lacking on the effects of resistance training on mechanisms of ketone body
clearance, the resulting increased skeletal muscle mass would have a positive
effect on insulin sensitivity31. This would decrease ketogenic activity via better
regulation of the glucagon/insulin ratio of glucagon and inhibiting ketogenesis
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promoting hormones20. Resistance training, like aerobic training, has also been
shown to increase MCT1 expression in certain trials79.
While positive effects of aerobic training on ketone metabolism have been
documented, there are large gaps in current knowledge regarding the effects of
resistance training and concurrent training on ketone metabolism. Therefore,
further research is required to determine the potential benefits of exercise
programs for ketone body metabolism. It is also not known how exercise induced
changes in ketones correlate with changes in some other important concomitant
cardiometabolic biomarkers related to T2DM, such as HbA1c, C-reactive protein,
and lipid panel. There is no accepted working model as to the exact physiological
mechanisms underlying enhanced ketone metabolism from exercise, and
therefore the biological plausibility needs to be examined.
Exercise increases BCAA catabolism by increasing BCKDH activity while
reducing BCKDH kinase activity. One proposed mechanism behind this effect is
exercise-induced increases in adiponectin expression80, 81 and the subsequent
activation of downstream substrates. Adiponectin is a protein hormone produced
in adipose tissue that has roles in regulating glucose levels, fatty acid
breakdown81 and has more recently been shown to be linked to BCAA
catabolism82. One mechanism of action for adiponectin is activation of 5’
adenosine monophosphate-activated protein kinase (AMPK)83. Adiponectin,
specifically through its downstream substrate AMPK works to activate PP2Cm.
This causes an overall shift towards dephosphorylation of BCKDH82.
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Dephosphorylated BCKDH is free to catalyze the decarboxylation of BCKA 60, 82
(Figure 2.1).
Both aerobic training and resistance training have well established
mechanisms behind physiological adaptions which improve insulin sensitivity to
decrease ketone levels56, 30, 31. Ketogenesis becomes inhibited due to decreased
release of ketogenic hormones; hormone-sensitive lipase, acetyl-CoA
carboxylase, and mitochondrial HMG-CoA synthase55. However, the role of
exercise on lowering ketones via mechanisms controlling ketolytic enzymes is
less clear. MCT1, a plasma membrane transporter, catalyzes the proton-linked
transport of monocarboxylates which includes not only ketones, but pyruvate and
lactate, which are accumulated during exercise and transported in the cell to go
through the TCA cycle to produce ATP78, 84. Lactate accumulation increases with
increasing intensity of exercise85, which causes an increase in MCT1 activity78, 86.
MCT1 communicates with basigin (CD147), a cell surface glycoprotein, which
facilitates MCT1 turnover. As the activation of these transporters increases
during exercise, CD147 causes an acute increase in degradation of MCT1
through activation of matrix metalloproteinase-2/9 as well as directly increasing
MCT1 transcription87. Increased CD147 activity results in upregulation and
increased expression of MCT1 in heart and skeletal muscle which increases
ketone body uptake into the cells for utilization in the TCA cycle (Figure 2.2).
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Exercise

Adiponectin↑↑↑

AdipoR1/2

APPL1 ↑ ↑

Rab5

BCAA
AMPK
PP2cM
BCKA

BCKDH

miR-22
BCKDH
Kinase

AcetylCoA/SuccinylCoA

Figure 2.1 Hypothetical working model of the effect of exercise on BCAA
metabolism.
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Exercise

Lactate↑ ↑ ↑

MCT1 activity
↑

Ketone influx
↑

CD147

MMP
2/9

MCT1
Synthesis↑

MCT1
degradation
↑

Figure 2.2 Hypothetical working model of the effect of exercise on ketone body
metabolism.
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CHAPTER 3
METHODOLOGY
Study Design and Participants:
The current study will be performed as a secondary analysis of the Health
Benefits of Aerobic and Resistance Training in individuals with Type 2 Diabetes
(HART-D) trial. The full design and methodology of the HART-D trial has been
published previously56. Briefly, HART-D was a 9-month randomized, controlled
exercise-training trial comparing the effects of different modalities of exercise
training on HbA1c levels in sedentary participants with T2DM. A total of 262
participants were recruited from the greater Baton Rouge, Louisiana area. They
were then randomized to one of four groups; a non-exercise control group, an
aerobic training group (AT), a resistance training group (RT), or a combination of
aerobic and resistance training group (ATRT). Exclusion criteria for the study
included a BMI >48 kg/m2, age <30 or >75 years, blood pressure ≥160/100
mmHg, fasting triglyceride levels ≥500 mg/dL, use of insulin pump, urine protein
levels >100 mg/dL, history of stroke, and advanced neuropathy or retinopathy or
any serious medical condition that prevented adherence to the study protocol or
the ability to exercise safely. For the current study, participants (n=180) who
completed greater than 70% of their prescribed exercise program and had
complete data were included in the per-protocol analysis. consent was obtained
from all participants prior to screening. All training sessions were performed
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under staff supervision in an exercise training laboratory at Pennington
Biomedical Research Center, Baton Rouge, Louisiana.
Exercise Interventions:
Participants in the AT group (n=44) exercised 3–5 days/week at an
intensity of 50–80% of their VO2 peak fitness for a total dose of 12 kcal/kg/week
(KKW), which is estimated to be equivalent to the 150 minutes of physical activity
per week recommended by the federal activity guidelines88. The caloric dose was
adjusted on a weekly basis based on changes in body weight. American College
of Sports Medicine equations were used to estimate caloric expenditure rates
and, therefore, the time required per session89.
The RT group (n=49) exercised 3 days/week, with each session consisting
of two sets of four upper-body exercises (chest press, lateral pull-down, military
press, and seated row), three sets of three lower-body exercises (leg press, leg
extension, and hamstring curl), and two sets of abdominal and back exercises.
Each set consisted of 10–12 repetitions. The prescribed weight was increased
when the participant was able to complete 12 repetitions of a final set of each
exercise on two consecutive sessions.
The ATRT group (n=54) had the same guidelines for performing their
aerobic training but had a lower weekly dose of 10KKW. The resistance training
for the ATRT group required two sessions per week, with each session
consisting of one set of each of the aforementioned nine exercises. They also
used a progressive increase in weight when 12 repetitions could be performed on
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an exercise, as described above. The training regimen for the combination
training group was consistent with federal physical activity guidelines88 and
ensured equal time commitment among all exercise groups. The non-exercise
control group (n=33) was offered weekly stretching and relaxation classes and
was asked to maintain their baseline activity levels during the 9-month study
period.
BCAA and Ketone body measurement:
After a 10 hour fast, blood samples were obtained at baseline. Posttraining blood sampling was performed 24-48 hours after completion of the final
exercise session and after a 10 hour fast. Plasma ketone and BCAA levels were
quantified by nuclear magnetic resonance spectroscopy (NMR) at LabCorp
(Morrisville, NC) using an optimized version of NMR LipoProfile algorithm
(LP4)90. The methyl groups of the 3 branched-chain amino acids (valine, leucine,
isoleucine) give rise to characteristic signals in the 1H NMR spectrum that enable
their accurate quantification as validated by comparison with LC/MS/MS values 91.
The three ketone bodies (3-β-hydroxybutyrate, acetoacetate, acetone) give rise
to resolved NMR signals that serve as the basis of their quantification91.
Demographic and Cardiometabolic phenotypes measurement:
Weight was measured on a GSE 450 electronic scale (GSE Scale
Systems, Novi, Michigan) and height was measured using a standard
stadiometer. Lean mass and fat mass were measured by Dual x-ray
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absorptiometry scans using the QDR 4500A whole-body scanner (Hologic Inc,
Bedford, Massachusetts).
Diabetes status and duration was confirmed by medical history review.
Diabetes medication type and dosage were assessed by detailed questionnaire
with visual confirmation of prescription bottles. Participants were categorized as
either increased, decreased, or no change in diabetes medications based on
baseline and follow-up medication dosages. Race/ethnicity was obtained through
written self-report.
HbA1c was assessed from a finger prick sample run on an automated
glycosylated hemoglobin analyzer (DCA2000+, Bayer, Dublin, Ireland). Fasted
blood samples from baseline and post-intervention clinic visits were used to
measure glucose and insulin levels. Glucose levels were analyzed on a DXC 600
Pro (Beckman Coulter Inc, Brea, California). Insulin was measured using an
immunoassay on the Siemens 2000 (Siemens, Deerfield, Illinois).
Exercise testing to determine VO2peak was conducted on a treadmill
(Trackmaster 425, Carefusion, Newton, Kansas), with respiratory gases sampled
using a True Max 2400 Metabolic Measurement Cart (Parvomedics, Salt Lake
City, Utah).
For all continuous variables, change in response to the exercise training
program (Δ) was calculated by subtracting the baseline value from the posttraining value.
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Statistical Analysis:
Primary outcome analyses used the per-protocol principle and included
only participants who completed greater than 70% of their prescribed exercise
program (n=180).
Within-group exercise induced changes in levels of circulating BCAA and
ketones were analyzed using a paired t-test. Exercise induced changes in levels
of circulating BCAA (total, leucine, isoleucine, valine) and ketones (total, AcAc,
BHB, acetone) were analyzed between intervention groups using generalized
linear regression models adjusting for age, race, sex, Δfat mass, Δglucose,
cholesterol and blood pressure medications, diabetes medication changes, and
baseline trait value. If the main effect of intervention group showed a p-value
<0.05 in the model, post-hoc analyses determined between-group differences in
adjusted least squared means values across all pairwise comparisons (Aim 1).
As an exploratory analysis for aim 1, changes in total circulating BCAA
levels were analyzed within intervention groups using unadjusted generalized
linear regression models stratified by baseline total circulating BCAA levels.
Participants were stratified as less than/equal to or greater than the proposed risk
cut-off threshold of 450 μmol/L.
Pearson Correlation analysis was used to determine the association
between exercise induced changes in circulating BCAA (total, leucine, isoleucine,
valine) and ketone (total, AcAc, BHB, acetone) levels (independent variable) and
changes in concomitant cardiometabolic biomarkers (HbA1c, fasting glucose,
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fasting insulin, CRP, lean mass, and body fat %) (dependent variable). Due to
the small sample sizes of the exercise intervention groups, all exercise groups
were combined for correlation analyses (Aim 2).
All statistical analyses were performed using SAS version 9.4 (Cary, NC).
P<0.05 was considered significant for all analyses.
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CHAPTER 4
RESULTS
Baseline characteristics, and average changes from baseline to postintervention, for participants by group including age, BMI, and other
cardiometabolic risk factors are shown in Table 4.1. No significant differences
were found between groups at baseline. Within exercise groups, ATRT
experienced an increase of 27.0 μmol/L for total BCAAs, 8.10 μmol/L in leucine,
and 6.69 μmol/L in isoleucine (all p<0.05) while no significant changes were
found in the AT or RT groups (Table 4.2). Between groups, the adjusted exercise
induced changes in total BCAA and leucine levels in the ATRT group were
significantly increased compared to the control and AT groups, while changes in
isoleucine levels in ATRT were significantly increased compared to other groups
(Table 4.3).
Within exercise groups, RT exhibited a -33.0 μmol/L decrease in BHB
(p<0.05) and was the only change in ketone bodies from the exercise program
(Table 4.4). The only significantly different change between groups in ketone
bodies was that the RT group had significantly larger decreases in BHB
compared with the AT group. The decrease in the RT group was not significantly
larger compared to the control group though (table 4.5).
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There was a large amount of heterogeneity in intraindividual responses to
the exercise program throughout all groups. There were large ranges in levels of
all traits at baseline and the changes in response to exercise varied within
groups. The SE of calculations for within-group changes in the exercise groups
ranged from 19.2–21.5 μmol/L in total BCAA levels (Table 4.2) and 23.4-26.3
μmol/L in total ketone body levels (Table 4.4).
Exercise induced changes in the outcome traits in all exercise training
groups combined were (p<0.05) correlated with changes in a few concomitant
cardiometabolic biomarkers (Table 4.6). Exercise induced changes isoleucine
were weakly, negatively correlated with the duration since diagnosis of T2DM
and weakly, positively correlated with fasting blood glucose levels. Changes in
total BCAA and valine levels were also moderately positively correlated with
changes in glucose. Changes in leucine levels were weakly negatively correlated
with change in VO2 peak. Total ketone body, BHB, and Acetone levels were all
weakly positively correlated with changes in HbA1c (Table 4.6).
When stratified by baseline total circulating BCAA levels, participants
across all exercise groups above the threshold at baseline (n=47) experienced
average decreases of 6.7 μmol/L, compared to 19.91 μmol/L increases
experienced across all exercise groups in participants below the threshold
(n=100) (p<0.05). Within exercise groups, those in the AT group above the
threshold experienced an average decrease of 28.73 μmol/L compared to 3.90
μmol/L increases experienced by those above the threshold in the AT group
(n=33) (p<0.05) (figure 4.1).
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Table 4.1. Participant baseline characteristics.
Variable

Timepoint

Control,
AT,
RT,
ATRT,
n=33
n=44
n=49
n=54
Age
58.6 (1.3)
52.7 (1.1)
56.9 (1.0)
55.4 (1.0)
2
BMI (kg/m ) Baseline
34.8 (1.0)
34.7 (0.7)
34.1 (0.6)
35.8 (0.7)
Change
0.2 (0.3)
-0.2 (0.2)
-0.2 (0.2)
-0.5 (0.2)
Body fat
Baseline
38.8 (1.2)
37.0 (1.2)
37.6 (1.1)
38.1 (0.9)
a
(%)
Change
0.2 (0.3)
-0.1 (0.3)
-1.2 (0.3)
-1.1 (0.2)a
Fat mass
Baseline
37.9 (2.1)
34.7 (1.4)
37.2 (1.4)
38.2 (1.6)
a
(kg)
Change
0.2 (0.6)
-0.3 (0.4)
-1.5 (0.4)
-1.7 (0.4)a
Lean mass Baseline
56.0 (2.1)
56.5 (1.7)
58.7 (1.5)
58.6 (1.7)
a
(kg)
Change
0.1 (0.4)
-0.4 (0.3)
0.8 (0.3)
0.0 (0.3)
VO2peak
Baseline
19.7 (0.7)
21.2 (0.8)
20.4 (0.7)
18.9 (0.5)
(mL/kg/min) Change
-0.3 (2.4)
0.5 (2.0)
0.3 (2.1)
1.3 (2.6)a
SBP
Baseline
127.1 (2.2) 124.5 (1.5) 124.2 (1.5) 129.4 (1.5)
(mmHg)
Change
1.9 (2.3)
-0.8 (2.0)
-0.9 (2.0)
-4.2 (1.9)a
DBP
Baseline
76.4 (1.3)
75.8 (1.1)
75.1 (1.0)
75.3 (18.9)
a
(mmHg)
Change
-3.8 (1.4)
-0.2 (1.4)
-0.1 (1.3)
-0.2 (1.2)
Insulin
Baseline
17.7 (2.3)
18.5 (2.0)
20.3 (1.7)
16.9 (6.3)
a
(pmol/L)
Change
-1.0 (2.2)
-1.7 (1.2)
-4.5 (1.7)
-0.8 (1.1)
HbA1c (%) Baseline
7.9 (1.3)
7.6 (1.0)
7.6 (0.9)
7.6 (1.0)
Change
0.1 (0.2)
-0.1 (0.2)
-0.2 (0.1)
-0.3 (0.1)a
Glucose
Baseline
158.4 (6.4) 146.4 (3.6) 153.8 (4.6) 148.8 (4.1)
(mg/dL)
Change
4.6 (8.8)
11.2 (6.5)
0.9 (5.9)
2.9 (4.1)
*All values expressed as means (standard error).
ap<0.05 for difference between post-training and baseline value from paired t-test
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Table 4.2. Within-group changes in BCAA traits.

Baseline
Intervention
Group

Follow-up

N

Withingroup
changes
Mean* SE

Mean SD Mean
SD
Total BCAA (μmol/L)
Control
33 402.5 66.4 397.9
67.5
-13.8 21.6
AT
44 407.5 68.5 403.3
67.8
-15.8 21.5
RT
49 419.3 86.4 426.8
80.3
3.2
21.1
ATRT
54 421.3 69.6 448.9a 103.4
27.0 19.2
Valine (μmol/L)
Control
33 224.7 40.2 222.8
35.1
-3.5
11.2
AT
44 226.0 33.4 227.1
33.9
-5.1
11.1
RT
49 235.3 42.4 236.1
42.1
1.2
10.9
ATRT
54 238.1 36.2 248.1
51.6
11.1
9.9
Leucine (μmol/L)
Control
33 120.2 21.1 122.6
26.1
-5.1
8.9
AT
44 123.4 28.5 118.2
30.7
-9.4
8.8
RT
49 122.4 35.2 129.7
31.2
1.7
8.7
a
ATRT
54 123.1 28.0 133.9
37.2
8.1
7.9
Isoleucine (μmol/L)
Control
33 57.7 14.7 55.3
14.1
-4.3
5.0
AT
44 58.2 15.5 58.0
15.7
-2.5
4.9
RT
49 61.5 17.1 61.1
16.5
-1.0
4.9
ATRT
54 60.0 14.4 66.9a
22.6
6.7
4.4
*Values adjusted for age, sex, race, change in fat mass and glucose, cholesterol
and blood pressure medication status, change in diabetes medication, and
baseline trait value.
ap<0.05 for difference between post-training and baseline value from paired t-test

33

Table 4.3. Between-groups comparison in BCAA traits.
Between-group: comparison vs
Control group changes
Intervention
pairwise
Group
N Mean*
95% CI
p-value
Total BCAA (μmol/L)
AT
44
-1.9
(-31.2 to 27.3)
0.90
RT
49 17.0
(-11.1 to 45.1)
0.24
ATRT
54 40.8a
(12.2 to 69.4)
0.005
Valine (μmol/L)
AT
44
-1.6
(-16.7 to 13.6)
0.84
RT
49
4.7
(-9.8 to 19.3)
0.53
ATRT
54 14.6
(-0.26 to 29.5)
0.054
Leucine (μmol/L)
AT
44
-4.4
(-16.5 to 7.7)
0.48
RT
49
6.7
(-5.0 to 18.4)
0.26
ATRT
54 13.1a
(1.2 to 25.0)
0.03
Isoleucine (μmol/L)
AT
44
1.8
(-4.9 to 8.5)
0.60
RT
49
3.3
(-3.2 to 9.8)
0.32
ATRT
54 11.0b
(4.4 to 17.5)
0.001
*Values adjusted for age, sex, race, change in fat mass and glucose, cholesterol
and blood pressure medication status, change in diabetes medication, and
baseline trait value
ap<0.05 for difference compared to AT group, bp<0.05 for difference compared to
all other groups
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Table 4.4. Within-group changes in ketone bodies traits.

Baseline

Follow-up

Intervention
Group

Withingroup
changes

N
Mean SD Mean
SD Mean* SE
Total Ketone Bodies (μmol/L)
Control
33 156.1 51.1 181.3 64.3
-15.7 26.4
AT
44 164.9 65.3 189.4 116.5
-8.3
26.3
RT
49 190.2 95.7 170.2 59.8
-49.3 25.8
ATRT
54 185.7 69.4 172.8 76.8
-30.5 23.4
Betahydroxybutyrate (BHB) (μmol/L)
Control
33
91.4 30.5 103.1 37.1
-15.4 16.4
AT
44
97.3 41.7 113.4 76.4
-3.4
16.3
RT
49 106.5 59.8 96.5a
37.8
-33.0 16.0
ATRT
54 105.4 42.5 99.8
43.3
-20.5 14.5
Acetoacetate (AcAc) (μmol/L)
Control
33
41.1 18.2 47.9
22.5
-0.6
8.2
AT
44
42.5 19.1 48.0
29.8
-2.7
8.2
RT
49
53.3 27.3 45.9
21.4
-10.8
8.0
ATRT
54
49.8 21.3 47.1
29.8
-4.7
7.3
Acetone (μmol/L)
Control
33
23.6 10.7 30.3
15.4
0.1
4.5
AT
44
25.1 13.2 28.0
15.9
-2.5
4.4
RT
49
30.4 15.7 27.8
10.7
-5.3
4.4
ATRT
30.4 13.9 25.9
12.3
54
-5.0
4.0
*Values adjusted for age, sex, race, change in fat mass and glucose, cholesterol
and blood pressure medication status, change in diabetes medication, and
baseline trait value.
ap<0.05 difference between post-training and baseline value from paired t-test
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Table 4.5. Between-group changes in ketone bodies traits.
Between-group: comparison vs
Control group changes
Interventi
on
Mean
pairwise
Group
N
*
95% CI
p-value
Total Ketone Bodies (μmol/L)
AT
44
7.4
(-28.4 to 43.2)
0.68
RT
49 -33.6
(-68.3 to 1.2)
0.06
ATRT
54 -14.8
(-50.1 to 20.6)
0.410
Betahydroxybutyrate (BHB) (μmol/L)
AT
44
12.0
(-10.2 to 34.3)
0.29
RT
49 -17.5a
(-39.0 to 4.0)
0.11
ATRT
54
-5.1
(-26.9 to 16.8)
0.65
Acetoacetate (AcAc) (μmol/L)
AT
44
-2.1
(-13.3 to 9.0)
0.71
RT
49 -10.2
(-21.1 to 0.6)
0.06
ATRT
54
-4.2
(-15.1 to 6.8)
0.46
Acetone (μmol/L)
AT
44
-2.6
(-8.7 to 3.4)
0.39
RT
49
-5.4
(-11.3 to 0.5)
0.07
ATRT
0.09
54
-5.1
(-11.1 to 0.9)
*Values adjusted for age, sex, race, change in fat mass and glucose, cholesterol
and blood pressure medication status, change in diabetes medication, and
baseline trait value.
ap<0.05 for difference compared to AT group.
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Table 4.6. Correlation between BCAA and ketone body traits and concomitant
cardiometabolic biomarkers
T2DD

bf%

lean

CRP

HbA1c

insulin

glucose

mass

VO2
peak

BCAA

NS

NS

NS

NS

NS

NS

0.30

NS

Val

NS

NS

NS

NS

NS

NS

0.36

NS

Leu

NS

NS

NS

NS

NS

NS

NS

-0.18

Ileu

-0.17

NS

NS

NS

NS

NS

0.20

NS

KetBod

NS

NS

NS

NS

0.20

NS

NS

NS

BHB

NS

NS

NS

NS

0.21

NS

NS

NS

AcAc

NS

0.17

NS

NS

NS

NS

NS

NS

Acetone

NS

NS

NS

NS

0.17

NS

NS

NS

Values in bold indicate significant correlations. All correlations listed were
significant at p<0.05. NS, not significant (p>0.05). T2DD: duration since T2DM
diagnosis, bf%: body fat %, CRP: C-reactive protein.
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Change in BCAA Levels Stratified by Baseline Threshold
Groups
Change in BCAA levels (μmol/L)

All groups

AT

RT

ATRT

40
30
20

*

10
*

0
-10

*

-20
-30
-40

*

Exercise Group

Baseline BCAA <=450 μmol/L

Baseline BCAA >450 μmol/L

Figure 4.1. Change in BCAA levels stratified by baseline threshold groups.
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CHAPTER 5
DISCUSSION
Our findings do not support our hypothesis that all exercise modalities
would result in significant decreases in BCAA and ketone body levels, as no
exercise groups showed a significant decrease in any outcome trait when
compared with the control group. In fact, we found significant exercise induced
increases in measures of isoleucine in the ATRT group compared to controls.
Exercise induced changes over the nine-month period in some of the BCAA and
ketone bodies also showed some weak and moderate correlations with
concomitant cardiometabolic biomarkers such as bf%, glucose, HbA1c, and VO 2
peak. To our knowledge this is the first large scale randomized exercise control
trial that has analyzed the changes in circulating BCAA and ketone body levels in
response to different long-term exercise training modalities in type 2 diabetics.
While the existing body of literature suggests that aerobic training
improves both BCAA and ketone body metabolism, this studies results did not
find the aerobic, resistance, or combination training provided any significant
benefits (i.e., decreased levels) for circulating BCAA or ketone body metabolism
in those with T2DM. The RT group experienced a significantly larger decrease in
BHB levels compared to the AT group, however this change was not different
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than the control group. Moreover, the AT group experienced decreased
levels compared to the AT and ATRT groups, but not different compared to the
control.
The baseline levels of participants in this study for both circulating BCAA
and Ketone body levels are consistent with the elevated levels expected for type
2 diabetics from previous research. The average total circulating ketone bodies
within exercise groups in this study ranged from 156 μmol/L to 190 μmol/L
compared to 182 μmol/L that was found to be the average level in a cohort of 373
subjects with T2DM in the Insulin Resistance Atherosclerosis Study (IRAS)
cohort91. As expected, these levels are elevated compared to the average of nondiabetic subjects from the IRAS cohort, who had average circulating ketone body
levels of 142 μmol/L91. Diabetics from the IRAS cohort had average levels of
circulating BCAAs of 393 μmol/L, which was significantly elevated compared to
the average of the non-diabetic cohorts (337 μmol/L)5. The average circulating
levels of BCAAs in the HART-D cohort within groups range from 403 μmol/L to
421 μmol/ which is similar to the elevated levels that were found in the IRAS
cohort.
While increased circulating BCAA levels are associated with increased
risk for CVD and associated metabolic risk factors, there is some evidence that
there may be a cut-off threshold that exists where increased BCAAs become a
risk biomarker. Sun et al.92 calculated this threshold concentration to be
approximately 450 μmol/L in a longitudinal study of over 600 people. Results
from a 2019 study support this proposed cut-off threshold. They found that for
40

males, compared to their reference group (Total BCAA concentration <361.9
μmol/L), only those in the upper quartile of their cohort (>448 μmol/L) were at a
significantly increased risk of incident hypertension (Hazard Ratio 1.36: 95% CI
1.11-1.68) after an 8 year follow up93. Despite their diabetic status, the average
BCAA concentration of participants in this study ranged was below that threshold
at baseline. When stratified into those that started above (n=47) or below (n=100)
this threshold from the exercise groups as an exploratory analysis, we did find
that those above decreased compared to those below across all exercise groups.
Those with baseline levels >450 μmol/L had an average change of -6.7 μmol/L
and those with baseline levels >450 μmol/L had an average change of 19.9
μmol/L. When examined by exercise group, those above the baseline threshold
in the AT group showed decreases in total BCAA levels compared to those
above the threshold at baseline. The RT group decreased but not significantly
different to the increases that were seen in those above the baseline, while the
ATRT group still exhibited increases.
Despite a body of literature suggesting that aerobic exercise increases
ketone body clearance acutely76-78, there were no decreases shown from any
exercise group. The RT group did experience decreases in BHB compared to
AT. As muscle mass is a key regulator in the regulation of glucagon and insulin
ratios31, an increase in lean mass mediated by resistance training may be a
potential mechanism behind RT experiencing larger decreases than AT.
Given the unhealthy metabolic status and age of the individual participants
the possibility of exercise resistance also may have played a factor. A notable
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quantity of non-responders to exercise in diabetic and obese individuals has
been observed for several traits including glucose and insulin sensitivity
measures94. Aging is also known to lead to anabolic resistance and nonresponse to exercise95. We found large heterogeneity in the exercise responses
across all eight traits, regardless of exercise modality or adherence. This
heterogeneity may be explained by a combination of numerous factors, such as
genetic and epigenetic factors, differing clinical profiles of individuals (despite
being similar at baseline), and other as of yet unknown factors.
Exercise may also just be a mediating factor for regulating concentrations
of these metabolites. Individuals who are physically fit (higher VO2max) and
have higher lean mass and lower fat mass have lower circulating BCAA levels
compared to obese individuals63. The relationship between fitness and BCAA
was minimally found in this study with a weak negative correlation between
leucine concentration and VO2 peak.
The relationship between ketone bodies and HbA1c levels is not well
established. Different associations have been shown between HbA1c and AcAc
and between HbA1c and BHB, between prediabetics and diabetics, and even
between sexes and different races96. Zhang et al96 found that increasing
concentrations of HbA1c were associated with decreasing concentrations of
acetoacetate in those with European background (regression coefficient in
males=−0.13: 95% CI −0.24 to −0.004, females −0.17: 95% CI −0.30 to −0.05),
but were associated with increasing concentrations of acetoacetate in African
Surinamese men (0.09: 95% CI 0.02–0.17) as well as subjects with Ghanaian
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background (males 0.13: 95% CI 0.05–0.20, females 0.08: 95% CI 0.01–0.154).
Total ketone bodies, BHB, and acetone showed a weak positive correlation with
HbA1c in this study, while AcAc showed no association, further suggesting that
while circulating ketone body concentrations and HbA1c may be associated, the
relationship is quite contentious. No mediating factor between the two biomarkers
is known.
Increase in BCAAs, especially isoleucine, has been shown to correlate in
increase with fasting glucose in both Caucasians (OR 1.021: 1.006-1.030), and
African Americans (OR 1.021: 1.006-1.038) without impaired fasting glucose96.
The correlation becomes even stronger in those with impaired fasting glucose,
Caucasians (OR 1.026: 1.015-1.037) and African-Americans (OR 1.034: 1.0191.050)96. Our results further support these findings although total circulating
levels of total BCAAs and valine were found to have a stronger correlation than
isoleucine.
Strengths of the HART-D study include that this is a large, randomized
control trial using a diverse population in age, sex, ethnicity, medication use, and
comorbidities leading to generalizable findings. All exercise sessions were tightly
controlled and completed in a laboratory and were monitored by exercise training
professionals. However, these ideal training conditions also represent a limitation
in terms of dissemination. A food frequency questionnaire was administered at
baseline and follow-up to assess changes in diet which limits the ability to identify
changes in caloric intake.

43

Although the findings from this study do not fully support our hypothesis
there is some evidence provided that different exercise modalities can have
different impacts in management of circulating BCAA and ketone body levels in
individuals with T2DM. Associations with other important cardiometabolic
biomarkers in diabetes such as HbA1c and fasting blood glucose levels also
further support the notion that ketone bodies and BCAAs are clinically significant
metabolites in the treatment and management of T2DM. As this was the first
large scale study looking at the association of different exercise modalities with
circulating BCAA and ketone body levels in diabetics more research is needed to
establish a better understanding of how exercise effects the concentrations of
these metabolites and the mechanisms that mediate these changes.
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